ArticleMolecular medicine reports2020
Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Dehydrocorydaline maintains the vascular smooth muscle cell contractile phenotype by upregulating Spta1.Acta pharmacologica Sinica · 2025Article
- Phenotypic profiling of small molecules using cell painting assay in HCT116 colorectal cancer cells.PloS one · 2025Article
- Plant-Based Anticancer Compounds With a Focus on Breast Cancer.Cancer reports (Hoboken, N.J.) · 2024Review
- Article
- miR-215-5p regulates osteoporosis development and osteogenic differentiation by targeting XIAP.BMC musculoskeletal disorders · 2022Article
- DHA ameliorates MeHg‑induced PC12 cell apoptosis by inhibiting the ROS/JNK signaling pathway.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dehydrocorydaline (DHC) is an alkaloid isolated from Corydali syanhusuo that exhibits antitumor properties. It has been reported that DHC can inhibit the proliferation of breast cancer cells, however the underlying molecular mechanism remains elusive. Therefore, the main objective of this study was to evaluate the antitumor activity of DHC, and gain further insights into its mechanism of action. The viability of MDA‑MB‑231 cells was determined through a Cell Counting Kit‑8 assay. The effect of DHC on the proliferation of MDA‑MB‑231 cells was detected by flow cytometry and 5‑ethynyl‑2'‑deoxyuridine staining. Apoptosis was evaluated by Annexin V‑FITC and PI staining through flow cytometry. The impact of DHC treatment on the colony‑forming ability of breast cancer cells was assessed. The expression levels of proliferation‑associated genes cyclin‑dependent kinases 1 (CDK1) and cyclin D1 (CCND1) and apoptosis‑related genes BCL2 and caspases 3/8/9 were quantified by real‑time PCR. Western blot analysis was performed to evaluate the production of cleaved caspase 3/9 and matrix metalloproteinase (MMP)2/9. DHC‑treated MDA‑MB‑231 cells were subcutaneously injected into mice. Subsequent immunohistochemical analyses were performed. DHC inhibited the viability, proliferation, colony‑forming ability and migration of MDA‑MB‑231 cells; in addition, DHC treatment promoted their apoptosis. DHC inhibited the production of proliferation‑ and anti‑apoptosis‑associated proteins CDK1, CCND1, BCL2 as well as that of the metastasis‑associated proteins MMP2 and MMP9. However, it promoted the expression of the pro‑apoptotic caspases 3/8/9. Moreover, DHC inhibited the growth of MDA‑MB‑231 tumor xenografts in SCID mice, and decreased cell proliferation in newly formed tumors in vivo. DHC exerted anticancer effects by downregulating cell proliferation, antiapoptosis, metastasis‑associated proteins CDK1, CCND1, BCL2 and metastasis‑associated proteins MMP2 and MMP9, and by upregulating the expression of proapoptotic proteins caspase 3/8/9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.